Reports Q4 revenue $4.36B, consensus $4.08B. “Iqvia (IQV) closed 2025 with strong performance across all segments,” said Ari Bousbib, chairman and CEO of Iqvia. “We delivered near double digit revenue and EPS growth, and the strongest quarter of the year in R&DS net bookings. In a challenging environment, Iqvia’s expanded go-to-market strategy, operational discipline, and investments in AI innovations led to clear differentiation and strong topline growth for both the commercial business and the clinical business in the quarter and for the year. This momentum positions us well for 2026 and beyond.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA: Improving Fundamentals, Easing Industry Headwinds, and 2026 Growth Visibility Support Buy Rating
- IQVIA Holdings (IQV) Q4 Earnings Cheat Sheet
- Iqvia, Boehringer Ingelheim announce data collaboration
- Novo Nordisk’s Wegovy Pill Records Nearly 20,000 Prescriptions in First Week
- Iqvia price target raised to $245 from $215 at TD Cowen